Prodeep Bose (who I can’t find on Twitter, but anyway…) writes:
« The central crux of the FDA’s ruling suggests that a company’s responsibility is for content posted and not the entirety of the social context. And the intent, if I were to derive one, is to enable—if not empower—pharma to engage in social marketing.
In fact, I would suggest that it is the responsibility of pharma to engage and dispel inaccuracies regarding its products with a genuine intent in doing just so, in a responsible manner. And I imagine that the positive thinker on either side of the regulatory fence, whether at FDA or pharma, would see eye to eye on furthering the goal of legitimate information dissemination through the most powerful means of communications in our time—social engagement. »
See on www.mediapost.com